ContraFect names Steven Gilman as Chief Executive Officer

The US firm is a developer of protein and anti-body therapeutics

ContraFect, a Yonkers, NY, US-based biotechnology company, has named Steven Gilman as Chief Executive Officer, effective immediately. Dr Gilman has been Interim Chief Executive since 21 March 2016. He will continue as Chairman of the Board of Directors of the company, which is focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases.

'The Board is pleased to have an executive with the experience and credentials of Steve Gilman to serve as Chief Executive Officer at ContraFect,' said Sol Barer, ContraFect's Lead Independent Director. 'Steve is a proven leader in the infectious disease field, and has extensive experience in the development and commercialisation of new anti-infective agents.'

You may also like

Research & Development

Fujifilm Diosynth supports anti-staph biologic development

Signs contract with ContraFect Corporation in the US
Packaging

Innovating primary packaging for parenteral drugs: challenges and future directions

The new challenges brought about by the pandemic call for an increasingly scientific approach to the evolution of single packaging elements in order to anticipate the needs of new drug formulations and guarantee a more enhanced, measurable and stable level of performance
Regulatory

US Pharmacopeia details mass spectrometry guidelines to advance biologics impurity control

The new chapter aims to standardise the use of mass spectrometry-based analysis in the biopharmaceutical industry, which can be used to detect impurities in cell and gene therapies, antibodies and other biologics
Packaging

How pharma packaging manufacturers role is evolving: the case of extractables testing

As the pharmaceutical industry continues to grow and evolve, extractables testing is a critical component of the pharmaceutical industry's efforts to prioritise quality and safety, ensuring one of the key functions pharma containers are designed for, says Anna Malori, Head of Product Management at Bormioli Pharma
Regulatory

Merck's Welireg approved for cancers associated with von Hippel-Lindau disease in China

The once-daily drug is the first HIF-2α to be approved in China, exhibiting a 49% objective response rate (ORR)
Manufacturing

Aurobindo Pharma signs $25m respiratory drug development and commercialisation deal with global pharma company

The companies will co-develop and commercialise respiratory therapeutics, diversifying Aurobindo's current portfolio
Packaging

Dual-chamber packaging systems as a simplification factor in the supply chain

Dual-chamber packaging solutions could represent a new frontier also to package parenteral drugs, simplifying the supply chain through reconstitution, potentially making logistics more flexible and efficient, says Cecilia Bassi, Product Manager at Bormioli Pharma
Subscribe now